Lantheus Holdings Inc specializes in diagnostic and therapeutic products for heart disease and cancer. Recent insider activity reveals more sales than purchases, with Director Gerard Ber selling shares. The company's market cap is $6.59 billion, with a P/E ratio of 15.56 below industry median.